UPMC Enterprises has contributed to a $20m series B extension for Cerevance, which is commercialising Rockefeller University research.
Cerevance, a US-based brain disease treatment company based on Rockefeller University research, yesterday increased its series B round to $65m following a $20m extension featuring UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center.
Dolby Family Ventures, Foresite Capital and Casdin Capital also backed the extension.
The extension comes three months after an initial $45m series B tranche backed by GV and Takeda Ventures, corporate venturing subsidiaries of internet and technology group Alphabet, and pharmaceutical…
